Abstract
This paper describes the development of nonmyeloablative marrow transplant programs that have little toxicity in a canine model and their translation to patients with malignant and nonmalignant hematological diseases.
MeSH terms
-
Ambulatory Care
-
Animals
-
Autoimmune Diseases / therapy
-
Bone Marrow Transplantation / physiology*
-
Dogs
-
Hematologic Diseases / therapy
-
Hematologic Neoplasms / therapy
-
Hematopoietic Stem Cells / physiology*
-
Humans
-
Transplantation Chimera*
-
Transplantation, Homologous / physiology